ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF) (2020 - 2026)

ARS Pharmaceuticals has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $397000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $397000.0, up 41.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (up 247.54% YoY), and the FY2025 annual result was $1.4 million, up 1630.38% from the prior year.
• Depreciation & Amortization (CF) came in at $397000.0 for Q1 2026 at ARS Pharmaceuticals, down from $417000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $417000.0 in Q4 2025 to a low of -$37000.0 in Q2 2022.
• The 5-year median for Depreciation & Amortization (CF) is $64500.0 (2023), against an average of $140812.5.
• Across the five-year window, Depreciation & Amortization (CF) sank 117.7% in 2022 and soared 2445.45% in 2025, its largest moves.
• ARS Pharmaceuticals' Depreciation & Amortization (CF) stood at $14000.0 in 2022, then surged by 614.29% to $100000.0 in 2023, then tumbled by 71.0% to $29000.0 in 2024, then jumped by 1337.93% to $417000.0 in 2025, then slipped by 4.8% to $397000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $397000.0 (Q1 2026), $417000.0 (Q4 2025), and $391000.0 (Q3 2025), per Business Quant data.